Holen Sie sich die Stockscreener-App
1.755
4.46%
0.075
Schlusskurs vom Vortag:
$1.68
Offen:
$1.75
24-Stunden-Volumen:
66,074
Relative Volume:
2.20
Marktkapitalisierung:
$3.00M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-6.91M
KGV:
-0.5383
EPS:
-3.26
Netto-Cashflow:
$-6.14M
1W Leistung:
-7.04%
1M Leistung:
-33.02%
6M Leistung:
-57.30%
1J Leistung:
-58.09%
1-Tages-Spanne:
$1.67
$2.0315
1-Wochen-Bereich:
$1.67
$2.09
52-Wochen-Spanne:
$1.67
$23.80
Galmed Pharmaceuticals Ltd Stock (GLMD) Company Profile
Firmenname
Galmed Pharmaceuticals Ltd
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie GLMD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GLMD
Galmed Pharmaceuticals Ltd
|
1.80 | 3.00M | 0 | -6.91M | -6.14M | -3.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
510.27 | 130.68B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
671.38 | 74.97B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
602.20 | 36.08B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.01 | 31.19B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
259.84 | 27.56B | 3.32B | -860.46M | -1.04B | -8.32 |
Galmed Pharmaceuticals Ltd Stock (GLMD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2020-05-22 | Herabstufung | B. Riley FBR | Buy → Neutral |
| 2020-02-04 | Eingeleitet | Craig Hallum | Buy |
| 2020-01-30 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2019-12-02 | Eingeleitet | Canaccord Genuity | Buy |
| 2018-12-12 | Eingeleitet | B. Riley FBR | Buy |
| 2018-08-02 | Bestätigt | Maxim Group | Buy |
| 2018-07-13 | Eingeleitet | Stifel | Buy |
| 2018-07-12 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-06-12 | Bestätigt | H.C. Wainwright | Buy |
| 2018-03-15 | Hochstufung | Maxim Group | Hold → Buy |
| 2018-02-14 | Herabstufung | Maxim Group | Buy → Hold |
| 2018-02-12 | Bestätigt | H.C. Wainwright | Buy |
| 2017-11-15 | Eingeleitet | ROTH Capital | Buy |
| 2017-08-08 | Bestätigt | H.C. Wainwright | Buy |
| 2017-07-31 | Bestätigt | Maxim Group | Buy |
| 2016-08-01 | Bestätigt | Maxim Group | Buy |
| 2016-07-06 | Fortgesetzt | ROTH Capital | Buy |
| 2016-03-28 | Fortgesetzt | H.C. Wainwright | Buy |
| 2015-06-23 | Eingeleitet | H.C. Wainwright | Buy |
| 2015-05-06 | Eingeleitet | Sun Trust Rbsn Humphrey | Buy |
Alle ansehen
Galmed Pharmaceuticals Ltd Aktie (GLMD) Neueste Nachrichten
Galmed Phar stock hits 52-week low at $1.75 amid challenges - Investing.com Australia
Galmed Phar stock hits 52-week low at $1.75 amid challenges By Investing.com - Investing.com South Africa
Galmed Pharmaceuticals (NASDAQ:GLMD) Share Price Passes Below Two Hundred Day Moving Average – Here’s What Happened - Defense World
Galmed Pharmaceuticals (NASDAQ:GLMD) Earns Sell Rating from Analysts at StockNews.com - Defense World
Galmed Pharmaceuticals Ltd. to Host Earnings Call - ACCESS Newswire
Galmed Phar stock hits 52-week low at $2.21 amid challenges - Investing.com Australia
Galmed Phar stock hits 52-week low at $2.21 amid challenges By Investing.com - Investing.com South Africa
Galmed Pharmaceuticals (NASDAQ:GLMD) Coverage Initiated at StockNews.com - Defense World
Galmed Pharmaceuticals (NASDAQ:GLMD) Now Covered by StockNews.com - Defense World
Galmed Pharmaceuticals (NASDAQ:GLMD) Coverage Initiated by Analysts at StockNews.com - Defense World
StockNews.com Begins Coverage on Galmed Pharmaceuticals (NASDAQ:GLMD) - Defense World
Galmed Phar stock hits 52-week low at $2.6 amid market challenges - Investing.com Nigeria
Galmed Phar stock hits 52-week low at $2.6 amid market challenges By Investing.com - Investing.com South Africa
Galmed Phar stock hits 52-week low at $2.71 amid market challenges By Investing.com - Investing.com South Africa
Galmed Phar stock hits 52-week low at $2.71 amid market challenges - Investing.com Nigeria
Galmed Pharmaceuticals: Q3 Earnings Snapshot - New Haven Register
Galmed Pharmaceuticals Embraces Market with New Sales Agreement - TipRanks
Galmed Pharmaceuticals Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Galmed Phar stock hits 52-week low at $2.73 amid challenges - Investing.com Australia
500: Something went wrong - Investing.com Canada
Galmed Pharmaceuticals Amends Equity Purchase Agreement - TipRanks
Acyl CoA Desaturase Market Current Status and Future Prospects - IndiaPolitics.com
galmed pharmaceuticals ltd. Earnings dates - RTTNews
EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In September 2024 – Where Do Tesla, Nvidia, Apple, DJT Stock Rank? - Benzinga
Galmed Pharmaceuticals (NASDAQ:GLMD) Stock Passes Above 50-Day Moving Average of $4.52 - Defense World
United States shares lower at close of trade; Dow Jones Industrial Average down 0.25% - MSN
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.25% - MSN
(GLMD) Long Term Investment Analysis - Stock Traders Daily
Galmed reports positive results for Aramchol in NASH study By Investing.com - Investing.com Australia
Galmed reports positive results for Aramchol in NASH study - Investing.com India
Galmed publishes Results from Aramchol Phase 3 Open Label part in Hepatology - PR Newswire
Post-Trade Analysis: Galmed Pharmaceuticals Ltd (GLMD) Slides -13.90, Closing at 8.05 - The Dwinnex
Take off with Galmed Pharmaceuticals Ltd (GLMD): Get ready for trading - SETE News
Understanding GLMD stock ratios for better investment decisions - US Post News
GLMD’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle
Optimistic Market Report Drives Galmed Pharmaceuticals (GLMD) Stock Upward - Stocks Telegraph
How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs - GlobeNewswire
Finanzdaten der Galmed Pharmaceuticals Ltd-Aktie (GLMD)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.28%
0.80%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):